Ir al menú de navegación principal Ir al contenido principal Ir al pie de página del sitio

Breast Implant–associated Anaplastic Large Cell Lymphoma in Colombia: Report of a Multidisciplinary National Registry

Linfoma anaplásico de células grandes asociado a implantes mamarios en Colombia: informe de un registro nacional multidisciplinario



Abrir | Descargar


Sección
Manejo Multidisciplinario

Cómo citar
Breast Implant–associated Anaplastic Large Cell Lymphoma in Colombia: Report of a Multidisciplinary National Registry.
Rev. colomb. hematol. oncol. [Internet]. 2022 Sep. 21 [cited 2024 Dec. 21];8(Supl):211-2. Disponible en: https://doi.org/10.51643/22562915.489

Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Carlos Andrés Ossa Gomez
    Alejandro Duque
      Ramiro Huertas Motta
        Ana Maria Fidalgo
          Giovanna Rivas Taffur

            Background: An estimated 43,390 breast augmentation surgeries (86,780 implants) and 1486 breast implant reconstructions are performed annually in Colombia, representing the second-most breast surgery destination in South America, the fourth in the western hemisphere, and the fifth country worldwide. No previous reports have evaluated the incidence of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) epidemiology or outcomes in a Hispanic population. Published data on the incidence of this disease in Colombia are unknown; therefore, a National Joint Multidisciplinary Committee was developed between the Colombian scientific societies of Mastology, Plastic Surgery, Hemato-Oncology, and the Invima (The National Food and Drug Surveillance Institute) to track national cases of BIA-ALCL. Materials and Methods: We performed a retrospective review (survey-based study) of historical cases since 2011–2019, and a prospective collection of all patients with a confirmed World Health Organization diagnosis of BIA-ALCL identified in a newly established National Registry of BIA-ALCL. The trial was approved by Institutional Review Board (IRB).


            Visitas del artículo 154 | Visitas PDF 124


            Sistema OJS 3.4.0.7 - Metabiblioteca |